ridaifen-B

Known as: RID-B compound

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2018

2018

The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects.

Lirit N. Franks, Benjamin M. Ford, Toshifumi Fujiwara, Haibo Zhao, Paul L. Prather
Toxicology and applied pharmacology
2018

Selective estrogen receptor modulators (SERMs) target estrogen receptors (ERs) to treat breast cancer and osteoporosis. Several… (More)

Is this relevant?

2013

2013

Ridaifen B, a tamoxifen derivative, directly binds to Grb10 interacting GYF protein 2.

Senko Tsukuda, Tomoe Kusayanagi, +7 authors Fumio Sugawara
Bioorganic & medicinal chemistry
2013

Ridaifen B (RID-B) is a tamoxifen derivative that potently inhibits breast tumor growth. RID-B was reported to show anti… (More)

Is this relevant?

2013

2013

Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement.

Yukitoshi Nagahara, Midori Takeyoshi, +12 authors Masahiko Ikekita
Biochemical and biophysical research…
2013

Autophagy is a self-proteolysis process in eukaryotic cells that results in the sequestering of intracellular proteins and… (More)

Is this relevant?

2008

2008

Induction of mitochondria-involved apoptosis in estrogen receptor-negative cells by a novel tamoxifen derivative, ridaifen-B.

Yukitoshi Nagahara, Isamu Shiina, Kenya Nakata, Akane Sasaki, Tomomi Miyamoto, Masahiko Ikekita
Cancer science
2008

Tamoxifen is an antagonist of estrogen receptor, which is used widely as an estrogen receptor-positive breast cancer drug that… (More)

Is this relevant?